PrimeCell™ VP of Research and Development Available to Discuss Alternatives to Embryonic Stem Cells
News Jun 05, 2006
PrimeCell™ Therapeutics has announced that its Vice President of Research and Development, Francisco Silva, will be available to comment on how the company's PrimeCell technology could expedite the movement from stem cell research to therapy.
Derived from adult germ-line stem cells, PrimeCell has been transformed into heart, nerve, bone and cartilage cells.
Countering the conventional wisdom that adult stem cells cannot be successfully reprogrammed to become pluripotent or a greater plasticity, Silva can present data and examples of PrimeCell Therapeutics' discovery.
The PrimeCell technology is relevant as Congress considers legislation authorizing various forms of non-embryonic stem cell research.
WHO: Francisco J. Silva, Executive Vice President of Research & Development for PrimeCell Therapeutics. Silva is a principal contributor to the company's intellectual property portfolio and oversees the development of all therapeutic platforms.
He is responsible for PrimeCell Therapeutics' current scientific progress and designs, and also implements the company's premier research developments.
WHAT: PrimeCell Therapeutics LLC, a newly formed subsidiary of PrimeGen Biotech LLC, is devoted exclusively to adult stem cell reprogramming.
Its next generation stem cell - PrimeCell™ - is the adult, non-embryonic stem cell designed to transforme into any cell type found in the body.
The company has introduced its murine model and initial human results for PrimeCell at several global stem cell conferences.
PrimeCell Therapeutics' research team includes scientists from around the globe, specializing in molecular biology and recombinant DNA technology, biochemistry, cell biology, genetics, neurobiology and more.
EVP Francisco Silva came from the Beckman Research Institute at City of Hope National Medical Center.
Chairman and CEO Thomas C.K. Yuen is renowned for turning technological promise into companies - first as co-founder, co-chairman and COO of AST Research, Inc., then as chairman, CEO and president of SRS Labs.
Edge Communications, Inc.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.